Vaccinations recommended in allogeneic BMT survivors
| Vaccine . | No. of doses . | Months or years after BMT . |
|---|---|---|
| Pneumococcal conjugate (PCV13) | 3-4 | 3+ mo |
| Pneumococcal polysaccharide (PPSV23) | 1 | 6+ mo |
| Haemophilus influenzae conjugate (Hib) | 3 | 6+ mo |
| Meningococcal conjugate (MCV4) | 2 | 6+ mo |
| Meningococcal type B (Men-B) | 2-3 | 6+ mo |
| Inactivated polio | 3 | 6+ mo |
| Hepatitis A | 2 | 6+ mo |
| Hepatitis B | 3 | 6+ mo |
| Human papillomavirus (ages 9-45 y) | 3 | 6+ mo |
| Inactivated influenza | Annually | 6+ mo |
| Measles-mumps-rubella | 1 (adults); 2 (children) | 2+ y |
| Varicella | 2 | 2+ y |
| Shingles | 1-2 | 2+ y |
| Vaccine . | No. of doses . | Months or years after BMT . |
|---|---|---|
| Pneumococcal conjugate (PCV13) | 3-4 | 3+ mo |
| Pneumococcal polysaccharide (PPSV23) | 1 | 6+ mo |
| Haemophilus influenzae conjugate (Hib) | 3 | 6+ mo |
| Meningococcal conjugate (MCV4) | 2 | 6+ mo |
| Meningococcal type B (Men-B) | 2-3 | 6+ mo |
| Inactivated polio | 3 | 6+ mo |
| Hepatitis A | 2 | 6+ mo |
| Hepatitis B | 3 | 6+ mo |
| Human papillomavirus (ages 9-45 y) | 3 | 6+ mo |
| Inactivated influenza | Annually | 6+ mo |
| Measles-mumps-rubella | 1 (adults); 2 (children) | 2+ y |
| Varicella | 2 | 2+ y |
| Shingles | 1-2 | 2+ y |